Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA Resorts To Citizen Petition On Biosimilar Naming

This article was originally published in The Pink Sheet Daily

Executive Summary

Trade group argues that if unique names will be required for biosimilars then they also should be required of innovator products following a manufacturing change that is approved based on comparability testing.

Advertisement

Related Content

FDA Claims Sole Authority Over Naming Of US-Licensed Biologics
Track-and-Trace Bill Clears House With New Electronic Labeling Language
Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Biosimilar Suffix Naming Idea Trips On Dispensing Problem

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel